Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Combined With CDK4/6i in First-line HR+/HER2- SNF4 Advanced Breast Cancer
NCT06447623Phase 3Active, not recruiting
- Sponsor
- Fudan University
- Start
- Jun 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Rivoceranib in breast cancer, sponsored by Fudan University. Started Jun 2024; status: active, not recruiting.
02
Drugs
Rivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06447623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06447623.